ANAPTYSBIO, INC. Disposal Group, Including Discontinued Operation, Assets, Noncurrent
ANAPTYSBIO, INC. (ANAB) had Disposal Group, Including Discontinued Operation, Assets, Noncurrent of $0 as of 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent · last filed 2026-09-21
- 2026-06-30: Disposal Group, Including Discontinued Operation, Assets, Noncurrent $0.00.
- 2025-12-31: Disposal Group, Including Discontinued Operation, Assets, Noncurrent $1.26M.
- 2024-12-31: Disposal Group, Including Discontinued Operation, Assets, Noncurrent $1.72M.
| Period end | Disposal Group, Including Discontinued Operation, Assets, Noncurrent |
|---|---|
| 2026-06-30 | $0.00 10-KT · filed 2026-09-21 |
| 2025-12-31 | $1.26M 10-KT · filed 2026-09-21 |
| 2024-12-31 | $1.72M 10-KT · filed 2026-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |